论文部分内容阅读
目的:探讨甘精胰岛素在糖尿病临床治疗当中的效果与体重控制方面的优势。方法:选取20例糖尿病患者,并平均分为两组,研究组10例患者采用甘精胰岛素进行治疗,对照组10例患者采用NPH胰岛素进行治疗,对两组患者进行12周治疗后的临床疗效以及体重进行观察与对照比较。结果:两组患者经过12周的治疗后,在血糖控制方面,研究组患者HbA1c下降了2%,对照组患者HbA1c下降了2.3%,组间差异无统计学意义(P>0.05);在体重控制方面,研究组患者体重减少了0.97kg,对照组患者则增长了1.24kg,组间差异具有统计学意义(P<0.05)。讨论:甘精胰岛素不仅能够有效控制糖尿病患者HbA1c的增长,还能够减轻患者的体重,避免因体重超重而带来的病情恶化甚至是死亡的发生,值得临床应用及推广。
Objective: To investigate the effect of glargine in the clinical treatment of diabetes and its advantages in weight control. Methods: Twenty diabetic patients were selected and equally divided into two groups. Ten patients in the study group were treated with insulin glargine and 10 patients in the control group were treated with NPH insulin. The clinical efficacy of the two groups after 12 weeks of treatment The body weight was observed and compared with the control. Results: After 12 weeks of treatment, HbA1c in study group decreased by 2% and HbA1c in control group decreased by 2.3% with no significant difference (P> 0.05) Control, the study group, weight loss of 0.97kg, while the control group increased by 1.24kg, the difference between groups was statistically significant (P <0.05). Discussion: Glargine not only can effectively control the growth of HbA1c in diabetic patients, but also can reduce the patient’s weight and avoid the deterioration of the condition caused by overweight and even death, which is worthy of clinical application and promotion.